Statin-mediated Cytoprotection of Human Vascular Endothelial Cells: a Role for Kruppel-like Factor 2-dependent Induction of Heme Oxygenase-1
Overview
Authors
Affiliations
Background: Heme oxygenase-1 (HO-1), by exerting anti-inflammatory, antiproliferative, antiapoptotic and antioxidant effects in the vasculature, protects against atherosclerosis and post-transplant vasculopathy. We noted the overlap between the effects of HO-1 and those attributed to 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). This led to an investigation of the role of HO-1 in statin-mediated cytoprotection in primary human endothelial cells (ECs), and the ability of Kruppel-like factor 2 (KLF2) to regulate HO-1 function.
Methods/results: Treatment of human umbilical vein and aortic ECs with atorvastatin significantly upregulated HO-1 promoter activity, mRNA expression and protein expression, increasing HO-1 enzymatic activity as shown by raised intracellular bilirubin IXalpha. This effect was indirect, dependent upon inhibition of HMG-CoA reductase and geranylgeranylation, and independent of nitric oxide or changes in mRNA stability. Atorvastatin protected ECs against the generation of reactive oxygen species and H(2)O(2)-induced injury. HO-1 inhibition, with small interfering RNA (siRNA) or zinc protoporphyrin IX, abrogated atorvastatin-mediated cytoprotection. Atorvastatin upregulated KLF2 expression, whereas KLF2 siRNA attenuated statin-induced HO-1 and its associated antioxidant cytoprotective effects. Iron chelation, adenoviral-mediated overexpression of ferritin or supplementation of culture media with biliverdin reversed the inhibitory effects of HO-1 and KLF2 siRNA, suggesting that bile pigments and ferritin mediate the antioxidant actions of statin-induced HO-1.
Conclusions: We have identified a novel link between KLF2 and HO-1 in human vascular ECs, demonstrating that atorvastatin-mediated HO-1 upregulation, and its associated antioxidant effect, is KLF2-dependent. The relationship between KLF2 and HO-1 is likely to represent an important component of the vasculoprotective profile of statins.
Liu J, Lei S, Zhang D, He Q, Sun Y, Zhu H Mol Med. 2024; 30(1):256.
PMID: 39707228 PMC: 11660731. DOI: 10.1186/s10020-024-01025-0.
Luo J, Zhu Q, Huang K, Wen X, Peng Y, Chen G PLoS One. 2024; 19(8):e0308823.
PMID: 39146322 PMC: 11326635. DOI: 10.1371/journal.pone.0308823.
Kounatidis D, Tentolouris N, Vallianou N, Mourouzis I, Karampela I, Stratigou T Metabolites. 2024; 14(7).
PMID: 39057711 PMC: 11278853. DOI: 10.3390/metabo14070388.
Paradoxical effects of statins on endothelial and cancer cells: the impact of concentrations.
Ahmadi Y, Khalili Fard J, Ghafoor D, Eid A, Sahebkar A Cancer Cell Int. 2023; 23(1):43.
PMID: 36899388 PMC: 9999585. DOI: 10.1186/s12935-023-02890-1.
The Effects of Statin Treatment on Serum Ferritin Levels: A Systematic Review and Meta-Analysis.
Jamialahmadi T, Abbasifard M, Reiner Z, Rizzo M, Eid A, Sahebkar A J Clin Med. 2022; 11(17).
PMID: 36079181 PMC: 9457426. DOI: 10.3390/jcm11175251.